StepStone Group’s NovoCure NVCR Stock Holding History

StepStone Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-115,479	Closed	-$7.3M	–	4
2019 Q2	$7.3M	Sell	115,479 -100,000	-46%	-$5.07M	11.05%	2
2019 Q1	$10.4M	Sell	215,479 -200,000	-48%	-$9.63M	4.98%	3
2018 Q4	$13.9M	Hold	415,479	–	–	19.11%	2
2018 Q3	$21.8M	Sell	415,479 -450,000	-52%	-$17.9M	21.72%	2
2018 Q2	$27.1M	Sell	865,479 -500,000	-37%	-$13.9M	28.71%	2
2018 Q1	$29.8M	Sell	1,365,479 -250,000	-15%	-$5.38M	21.9%	2
2017 Q4	$32.6M	Hold	1,615,479	–	–	22.75%	2
2017 Q3	$32.1M	Sell	1,615,479 -200,000	-11%	-$3.93M	21.2%	2
2017 Q2	$31.4M	Hold	1,815,479	–	–	19.07%	2
2017 Q1	$14.7M	Hold	1,815,479	–	–	16.24%	4
2016 Q4	$14.3M	Hold	1,815,479	–	–	17.28%	3
2016 Q3	$15.5M	Hold	1,815,479	–	–	19.27%	3
2016 Q2	$21.2M	Hold	1,815,479	–	–	26.31%	1
2016 Q1	$26.3M	Buy	+1,815,479	New	+$26.1M	36.57%	1

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

StepStone Group's NVCR Position: Q3 2019 in Review

StepStone Group sold out of NovoCure (NVCR) in Q3 2019, closing a stake of 115,479 shares — an estimated $7.3M sold.

StepStone Group first reported a position in NVCR in Q1 2016 and held it in 14 quarters. The position peaked at $32.6M in Q4 2017. 240 funds tracked by Wall St. Rank hold NVCR as of Q3 2019.

StepStone Group reported no remaining NovoCure position as of Q3 2019 after selling out during the quarter.
StepStone Group sold 115,479 NovoCure shares in Q3 2019, an estimated $7.3M.
StepStone Group first reported a position in NovoCure in Q1 2016 and held it in 14 quarters.
StepStone Group's NovoCure position peaked at $32.6M in Q4 2017.
240 funds tracked by Wall St. Rank held NovoCure as of Q3 2019.

Based on StepStone Group's 13F filing for Q3 2019, filed 12 Nov 2019.